- Digital health funding remains strong in 2025, with $9.9 billion raised through Q3 and megarounds driving record deal sizes.
- The third quarter yielded $3.5 billion raised across 107 deals, with deal activity dipping but rounds being larger on average.
- The average digital health deal size so far this year is $28.1 million, compared to $20.4 million in 2024.
- Rounds totaling $100 million or more have accounted for nearly 40% of all digital health funding this year.
Why it matters: The path to success for digital health companies is becoming less straightforward, with startups increasingly relying on unlabeled rounds and facing longer timelines to reach Series B.
The details:
- Many companies are raising unlabeled rounds between Series A and B, making it harder for investors to gauge which startups are truly ready to scale.
- The Series B stage has become a hurdle for digital health companies, with the median gap between their Series A and B rounds stretching to 27 months this year, up from 17 months for the 2023 cohort.
- The number of Series B deals has declined sharply, with only 30 rounds completed through the third quarter of 2025 — roughly half the annual volume seen over the past four years.
What they’re saying:
- “There’s a set of companies raising quickly at high valuations — and then there’s everyone else. For those navigating the tougher path, the playbook is to find the moat and double down on clear differentiators. We’ve seen companies break through when they hit a meaningful milestone—like landing a major distribution deal, getting FDA clearance, or proving commercial traction — that becomes the hook for the next round,” stated Becca Shmukler, partner at a venture capital firm.
The big picture: While venture funding appears steady on the surface, significant shifts in fundraising dynamics and strategic focus reveal a landscape where both startups and incumbents must be nimble and strategic to thrive.
The race:
- Digital health startups are using funding, partnerships, and M&A to build horizontal breadth and evolve from point solutions into comprehensive platforms.
- Incumbent EHR vendors are rapidly integrating once-differentiating startup workflows into their core systems, accelerating the market reset.
What investors want: With funding rebounding selectively, investors are focusing on leadership quality as the factor most likely to determine whether a company attracts or misses out on funding.
- Investors are looking for leaders who can translate innovation into sustainable growth, navigate complex reimbursement landscapes, and compete against entrenched incumbents.
- Strong leadership is viewed as a proxy for resilience and long-term value creation, reducing risk and building credibility with investors.
The bottomline: In the next wave of digital health growth, leadership will be the decisive factor in determining which companies thrive and which are left behind.